Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants

J Virol. 2001 Mar;75(5):2041-50. doi: 10.1128/JVI.75.5.2041-2050.2001.

Abstract

Naturally occurring human immunodeficiency virus (HIV-1) variants require the presence of CD4 and specific chemokine receptors to enter a cell. In the laboratory, HIV-1 variants that are capable of bypassing CD4 and utilizing only the CCR5 chemokine receptor for virus entry have been generated. Here we report that these CD4-independent viruses are significantly more sensitive to neutralization by soluble CD4 and a variety of antibodies. The same amino acid changes in the HIV-1 gp120 envelope glycoprotein determined CD4 independence and neutralization sensitivity. The CD4-independent envelope glycoproteins exhibited higher affinity for antibodies against CD4-induced gp120 epitopes but not other neutralizing ligands. The CD4-independent envelope glycoproteins did not exhibit increased lability relative to the wild-type envelope glycoproteins. The utilization of two receptors apparently allows HIV-1 to maintain a more neutralization-resistant state prior to engaging CD4 on the target cell, explaining the rarity of CD4 independence in wild-type HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • CD4 Antigens / metabolism*
  • CD4 Antigens / pharmacology
  • Cell Line
  • Giant Cells / physiology
  • HIV Antibodies / immunology*
  • HIV Antibodies / metabolism
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / metabolism
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • HIV-1 / metabolism*
  • Humans
  • Ligands
  • Molecular Sequence Data
  • Neutralization Tests
  • Receptors, CCR5 / metabolism
  • Recombinant Proteins / pharmacology
  • Transfection
  • Virus Shedding

Substances

  • CD4 Antigens
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Ligands
  • Receptors, CCR5
  • Recombinant Proteins
  • recombinant soluble CD4